Bio-Rad Laboratories Reaffirms 2026 Revenue Growth Guidance and Operating Margin Targets
Bio-Rad Laboratories (BIO) has reaffirmed its full-year 2026 guidance, projecting currency-neutral revenue growth to fall between -3% and 0.5%. The company also maintained its target for non-GAAP operating margins within the upper half of the 10% to 12% range. During the Q3 earnings call, President and COO Jonathan DiVincenzo noted that the third quarter marked progress in improving the company's overall operating and financial performance. The guidance reflects management's confidence in navigating current market conditions while focusing on margin optimization.
Tickers: $BIO